Evidence map›Paper›PMID 24260186›Full record

ArticlePloS one2013

Deciphering genomic alterations in colorectal cancer through transcriptional subtype-based network analysis.

Jing Zhu, Jing Wang, Zhiao Shi, Jeffrey L Franklin, Natasha G Deane, Robert J Coffey, R Daniel Beauchamp, Bing Zhang

Abstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jing ZhuDepartment of Biomedical Informatics, Vanderbilt University, Nashville, Tennessee, United States of America.
Jing Wang
Zhiao Shi
Jeffrey L Franklin
Natasha G Deane
Robert J Coffey
R Daniel Beauchamp
Bing Zhang

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8M
Understanding and Controlling p120 Dysfunction in CRCP50CA095103 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 2002 to 2017
$33.6M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Proteome Characterization CenterU24CA159988 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LIEBLER, DANIEL C · 2011 to 2016
$13.9M
TRANSFORMING GROWTH FACTORS IN COLONIC NEOPLASIAR01CA046413 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI COFFEY, ROBERT J. · 1988 to 2016
$8.8M
Clinical Proteomic Technology Assessment for CancerU24CA126479 · NCI · VANDERBILT UNIVERSITY · PI LIEBLER, DANIEL C · 2006 to 2010
$7.9M
REGULATION OF GUT EPITHELIAL CELL PROLIFERATIONR01CA069457 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BEAUCHAMP, ROBERT DANIEL · 1995 to 2016
$4.4M
SURGICAL STUDIES OF INTESTINAL GROWTH CONTROLR01DK052334 · NIDDK · VANDERBILT UNIVERSITY · PI BEAUCHAMP, ROBERT DANIEL · 1997 to 2011
$3.3M
Systems Approach to the Biological Basis of Colon Cancer MetastasesR01GM088822 · NIGMS · VANDERBILT UNIVERSITY · PI BEAUCHAMP, ROBERT DANIEL, ZHANG, BING · 2009 to 2012
$1.5M
NCI NIH HHS CA068485NCI NIH HHS CA069457NCI NIH HHS CA095103NCI NIH HHS CA126479NCI NIH HHS CA159988NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA095103NCI NIH HHS R01 CA046413NCI NIH HHS R01 CA069457NCI NIH HHS U24 CA126479NCI NIH HHS U24 CA159988NIDDK NIH HHS DK052334NIDDK NIH HHS P30 DK058404NIDDK NIH HHS R01 DK052334NIGMS NIH HHS GM088822NIGMS NIH HHS R01 GM088822
6 · The paper itself

Abstract

Both transcriptional subtype and signaling network analyses have proved useful in cancer genomics research. However, these two approaches are usually applied in isolation in existing studies. We reason that deciphering genomic alterations based on cancer transcriptional subtypes may help reveal subtype-specific driver networks and provide insights for the development of personalized therapeutic strategies. In this study, we defined transcriptional subtypes for colorectal cancer (CRC) and identified driver networks/pathways for each subtype. Applying consensus clustering to a patient cohort with 1173 samples identified three transcriptional subtypes, which were validated in an independent cohort with 485 samples. The three subtypes were characterized by different transcriptional programs related to normal adult colon, early colon embryonic development, and epithelial mesenchymal transition, respectively. They also showed statistically different clinical outcomes. For each subtype, we mapped somatic mutation and copy number variation data onto an integrated signaling network and identified subtype-specific driver networks using a random walk-based strategy. We found that genomic alterations in the Wnt signaling pathway were common among all three subtypes; however, unique combinations of pathway alterations including Wnt, VEGF and Notch drove distinct molecular and clinical phenotypes in different CRC subtypes. Our results provide a coherent and integrated picture of human CRC that links genomic alterations to molecular and clinical consequences, and which provides insights for the development of personalized therapeutic strategies for different CRC subtypes.

Indexed as

Colorectal NeoplasmsGenome, HumanNeoplasm ProteinsNeural Networks, ComputerAnimalsCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMiceWnt Signaling PathwayNeoplasm Proteins

Identifiers

PMID24260186
PMCPMC3829853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.